This FXR-mediated activation enhances intestinal barrier integrity and promotes closure of the gut-vascular barrier, counteracting microbiota-driven barrier disruption, reducing bacterial translocation, and alleviating hepatic steatosis and non-alcoholic steatohepatitis (NASH) phenotypes (Mouries et al., 2019). Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.